Clinical Trials
13
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Conditions
- Pulmonary Hypertension Associated With Interstitial Lung Disease
- Interventions
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-18
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 480
- Registration Number
- NCT07181382
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Device: Gereic Dry Powder Inhaler
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT06274801
- Locations
- 🇺🇸
University of Florida Health, Gainesville, Florida, United States
🇺🇸Washington University School of Medicine, St Louis, Missouri, United States
🇺🇸University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- GB002, Inc.
- Target Recruit Count
- 390
- Registration Number
- NCT05934526
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Valley Advanced Lung Diseases Institute, Fresno, California, United States
🇺🇸UC San Diego Medical Center (La Jolla), La Jolla, California, United States